Clinical Research Directory

Inclusion Criteria: * Patients diagnosed with erectile dysfunction (ED) with an inadequate response to phosphodiesterase type 5 inhibitors (PDE5 inhibitors) or to intracavernosal injections with Caverject or Bimix/Trimix (IIEF-15 questionnaire score ≤12). * Patients aged 30 years or older. * Patients who have provided informed consent to participate in the study. * Patients who, in the investigator's opinion, are able to comply with all clinical trial requirements. * Patients who agree to attend follow-up visits and undergo the required assessments. Exclusion Criteria: * Severe infections or diseases, or hepatic, renal, or bone marrow insufficiency, that, in the investigator's opinion, contraindicate participation in the study. * Known hypersensitivity to onabotulinumtoxinA (BoNT-A). * Patients who do not consent to participate in the study. * Patients younger than 30 years. * Patients who underwent robotic radical prostatectomy less than 6 months prior to study enrollment. * Patients with a known history of neurogenic injury. * Patients with a history of radiation therapy. * Patients with a known psychiatric disorder. * Patients with anatomical abnormalities of the penis. * Patients who do not agree to, or are unable to commit to, attending the scheduled follow-up visits.